Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes-Reference-Cited by-同舟云学术

Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes

Published:2022-09 Issue:9 Volume:22 Page:670-679
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Zeidan Amer M.,Joshi Namita,Kale Hrishikesh,Wang Wei-Jhih,Corman Shelby,Salimi Tehseen,Epstein Robert S.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference33 articles.

1. Emerging treatment options for patients with high-risk myelodysplastic syndrome;Bewersdorf;Ther Adv Hematol,2020

2. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger);Fenaux;Ann Oncol,2021

3. Surveillance, Epidemiology, and End Results Program. SEER*Explorer. Myelodysplastic syndromes (MDS). 2021. Available at: https://seer.cancer.gov/explorer/index.html. Accessed 10 June 2021.

4. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it;Zeidan;Blood Rev,2019

5. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine;Hematology Reports;2024-02-28

2. Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms;Therapeutic Advances in Hematology;2024-01

3. Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices;Leukemia & Lymphoma;2023-09-07